Clinical Trials Logo

Filter by:
NCT ID: NCT05362604 Completed - Clinical trials for Antenatal Management of the Fetal Gastrointestinal Atresia

Prenatal Diagnosis of the Fetal Esophageal or Intestinal Atresia

DANATRESIA
Start date: April 1, 2021
Phase:
Study type: Observational

Aim- to investigate how prenatal diagnosis of fetal esophageal or intestinal atresia impacts obstetric and neonatal outcomes. Methods- This was a retrospective cohort study at a single center. The study population comprised 51 consecutive pregnancies, including 29 mothers (57%) and their fetuses affected by prenatally diagnosed fetal esophageal or intestinal atresia, and 22 mothers (43%) and their babies with postnatally diagnosed fetal esophageal or intestinal atresia.

NCT ID: NCT05362565 Not yet recruiting - Monogenic Obesity Clinical Trials

Genetic Research of Monogenic Obesity in a Pediatric Cohort With Severe and Early Onset Obesity

OBEGENE
Start date: October 1, 2022
Phase:
Study type: Observational

Obesity is a frequent disease mainly caused by environmental/polygenic factors and more rarely caused by the alteration of a single gene ("monogenic obesity"). The diagnosis of these rare forms can lead to personalized management (new treatments, prognosis, adapted hygienic and dietary rules) and family screening. The use of a panel covering the known causes of monogenic obesity on a pediatric cohort of severe and early obesity will allow to evaluate the relevance of these analyses to adapt the management of this type of patients.

NCT ID: NCT05362370 Enrolling by invitation - Clinical trials for Craniofacial Abnormalities

Stryker PEEK Customized Implant: A Prospective Post Market Follow Up to Evaluate Safety, Performance and Effectiveness

Start date: February 1, 2023
Phase:
Study type: Observational

The purpose of this study is to confirm the safety, performance and effectiveness of Stryker's PEEK Customized Implants when used for the augmentation and/or restoration of bony and/or soft tissue deformities in the cranial and craniofacial skeleton. The study is designed as a prospective, multi-center trial with a long-term follow-up (24 months) of study participants.

NCT ID: NCT05362006 Completed - Multiple Sclerosis Clinical Trials

Exopulse Mollii Suit, Spasticity & Tissue Oxygenation

ENNOX
Start date: March 1, 2022
Phase: N/A
Study type: Interventional

Spasticity is a frequent and debilitating symptom in patients with multiple sclerosis (MS). Sustained contractile activity, such as that observed in spastic muscles, could reduce the capillary density and induce important changes in the muscular microcirculation, leading to oxidative changes within the muscular tissue. Such changes reflect altered aerobic metabolism and impaired mitochondrial function. The available therapeutic strategies for treating spasticity and related symptoms are usually faced with limited efficacy and numerous side effects. For these reasons, non-invasive stimulation techniques, namely transcutaneous stimulation by means of Exopulse Mollii suit, might be of help in this context.

NCT ID: NCT05361928 Completed - Muscle Injury Clinical Trials

IS ElastomEtry Useful in Muscle Lesion evaluaTion-REPROducibility Study

ISEULT-Repro
Start date: January 10, 2021
Phase:
Study type: Observational

Our objective is to evaluate the inter and intra observer reproducibility of the measure of elasticity using Acoustic Radiation Force Impulse (ARFI) ultrasonography of mucles of patients with and without hamstring injury. 76 patients will be evaluated cross sectionally twice by two ultrasonographists.

NCT ID: NCT05361603 Recruiting - Hepatitis C Clinical Trials

Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures

SCANVIR
Start date: May 24, 2017
Phase:
Study type: Observational

The principle is to propose dedicated monthly screening days bringing together the health personnel involved (hepatologist, addictologist, nurse in charge of the program, addictology nurse and social worker) and to propose appropriate management for each situation assessed.

NCT ID: NCT05361577 Completed - Clinical trials for Fibromyalgia, Primary

Exopulse Mollii Suit and Fibromyalgia

EXOFIB
Start date: March 1, 2022
Phase: N/A
Study type: Interventional

Fibromyalgia is a debilitating pain condition that is characterized by the chronic occurrence of pain affecting the musculoskeletal system, a sensitivity to pressure stimuli, and a low threshold to noxious stimuli. The topography of pain is widespread, although it could be more pronounced in some bodily regions. Besides pain, patients suffer from a wide range of symptoms, including fatigue, anxiety and depression manifestations, and altered quality of life. Facing these debilitating symptoms, the available therapeutic strategies for treating pain and associated manifestations are usually faced with limited efficacy and numerous side effects. For these reasons, non-invasive stimulation techniques, namely transcutaneous stimulation by means of Exopulse Mollii suit, might be of help in this context. The investigators designed a randomized sham controlled double-blind trial to demonstrate the improvement of pain, quality of life, fatigue and mood in adult patients with fibromyalgia following a 2-week intervention of "active" versus "sham" Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes.

NCT ID: NCT05361434 Recruiting - Clinical trials for Advanced Renal Cell Carcinoma

A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults

CaboCombo
Start date: September 26, 2022
Phase:
Study type: Observational

The purpose of this study is to collect data to describe the safety and effectiveness of cabozantinib and nivolumab in combination as a first-line treatment in adults with aRCC with clear cell-component, according to real-world clinical practice. The decision to prescribe cabozantinib and nivolumab in combination will be made prior to, and independently from, the decision to enrol the participant in study.

NCT ID: NCT05361395 Recruiting - Clinical trials for Extensive Stage Small Cell Lung Cancer

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Start date: August 24, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.

NCT ID: NCT05361317 Recruiting - Hallux Valgus Clinical Trials

Correction of Hallux Valgus With the Nexis® PECA Bunion Implantable Osteosynthesis Medical Device

PECA
Start date: June 13, 2022
Phase: N/A
Study type: Interventional

The Nexis® screw system is a range of osteosynthesis screws for the foot. Nexis® Bunion Screws are Class IIb implantable medical devices. The primary objective of the study is to confirm the performance and effectiveness of the device under investigation for the correction of hallux valgus with the evaluation functional capacities of the patient's foot. It will be assessed with "general sub-score" of the EFAS questionnaire determined during the postoperative visit at 6 months. The evaluation of quality of life scores, angular correction, bone consolidation and occurrence of adverse events will also be carried out.